Dorff, T.B.; Kasparian, S.; Garg, N.; Liu, S.; Pal, S.K.; Wong, J.; Dandapani, S.
Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches. J. Clin. Med. 2023, 12, 2011.
https://doi.org/10.3390/jcm12052011
AMA Style
Dorff TB, Kasparian S, Garg N, Liu S, Pal SK, Wong J, Dandapani S.
Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches. Journal of Clinical Medicine. 2023; 12(5):2011.
https://doi.org/10.3390/jcm12052011
Chicago/Turabian Style
Dorff, Tanya Barauskas, Saro Kasparian, Natasha Garg, Sandy Liu, Sumanta Kumar Pal, Jeffrey Wong, and Savita Dandapani.
2023. "Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches" Journal of Clinical Medicine 12, no. 5: 2011.
https://doi.org/10.3390/jcm12052011
APA Style
Dorff, T. B., Kasparian, S., Garg, N., Liu, S., Pal, S. K., Wong, J., & Dandapani, S.
(2023). Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches. Journal of Clinical Medicine, 12(5), 2011.
https://doi.org/10.3390/jcm12052011